Study guide
13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina
IJCAHPO Certified Retina Technician CRT
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview: Current CRT Requirements & Blueprint
Exam Overview: Current Requirements, Scope & Study Plan
2 Chapter 1: History Taking, Triage & Clinical Documentation
1.1 Comprehensive Ophthalmic & Medical History for Retina Patients 1.2 Telephone Triage, Urgent Symptoms & Emergency Scheduling 1.3 Scribing, Electronic Health Records & Retinal Billing Codes
3 Chapter 2: Visual Assessment & Low Vision Rehabilitation
2.1 Standardized Visual Acuity Testing & Optotypes 2.2 Sub-Chart Acuity Protocols: CF, HM, LP, and NLP 2.3 Low Vision Definitions, Optical Devices & Patient Counseling
4 Chapter 3: Pupil Assessment & Visual Field Testing
3.1 Pupillary Examination & Relative Afferent Pupillary Defect 3.2 Confrontation Fields & Automated Perimetry in Retina 3.3 Amsler Grid Testing & Metamorphopsia Monitoring
5 Chapter 4: Tonometry & Ocular Motility
4.1 Goldmann Applanation & Handheld Tonometry Techniques 4.2 Tonometer Disinfection, Calibration & Post-Procedure IOP Monitoring 4.3 Ocular Motility Assessment, Strabismus & Alignment Testing
6 Chapter 5: Diagnostic Ophthalmic Ultrasound
5.1 Ophthalmic B-Scan Echography for Posterior Segment Pathology 5.2 Standardized A-Scan Echography & Optical Biometry
7 Chapter 6: Slit Lamp, Electrophysiology & Supplemental Testing
6.1 Slit Lamp Biomicroscopy, Illumination & Fundus Lenses 6.2 Color Vision Assessment & Hertel Exophthalmometry 6.3 Ophthalmic Electrophysiology: ERG, VEP, and EOG
8 Chapter 7: Ophthalmic Microbiology & Infection Control
7.1 Ocular Pathogens & Routes of Disease Transmission 7.2 Clinical Asepsis, Universal Precautions & Vitreous Specimen Collection
9 Chapter 8: General Retinal Pharmacology & Therapeutics
8.1 Ocular Drug Delivery Methods & Routes of Administration 8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes 8.3 Anesthetics, Glaucoma Agents & Prescription Verification
10 Chapter 9: Anti-VEGF Therapies, Steroids & Retinal Toxicity
9.1 Anti-VEGF Agents & Neovascular Retinal Diseases 9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements 9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening
11 Chapter 10: Surgical Assisting & Intravitreal Procedures
10.1 Intravitreal Injection Protocol, Antisepsis & Complication Checks 10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols 10.3 Surgical Instrument Handling, Tray Setup & Sterilization
12 Chapter 11: Patient Services, Education & Clinical Care
11.1 Patient Education, Chronic Disease Counseling & Treatment Adherence 11.2 Special Needs Accommodations, Patient Diversity & Interpersonal Skills 11.3 Ophthalmic Emergencies, First Aid & Clinical Care Coordination 11.4 Clinic Operations, Research Support, Forms & Referrals
13 Chapter 12: General Ocular Anatomy & Retinal Physiology
12.1 Ocular Anatomy, Orbit & Posterior Segment Architecture 12.2 Ten Retinal Layers, Photoreceptors & Macular Anatomy 12.3 Ocular Blood Supply, Microcirculation & Vitreoretinal Interface 12.4 Body Systems, Ocular Adnexa & Medical Terminology
14 Chapter 13: Retinal Pathology & Systemic Disease Manifestations
13.1 Age-Related Macular Degeneration & Retinal Vascular Occlusions 13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina 13.3 Peripheral Retinal Degenerations, Tears & Detachments
15 Chapter 14: Ophthalmic Optics & Lensometry
14.1 Principles of Ophthalmic Optics & Refraction 14.2 Manual & Automated Lensometry Techniques
16 Chapter 15: Fundus Photography & Ophthalmic Angiography
15.1 Fundus Photography Techniques & Fundus Autofluorescence 15.2 Fluorescein Angiography Principles, Phases & Image Interpretation 15.3 Indocyanine Green Angiography & Angiographic Complication Management
17 Chapter 16: Optical Coherence Tomography (OCT & OCT-A)
16.1 OCT Principles, Scan Acquisition & Artifact Recognition 16.2 Structural OCT Interpretation: Retinal Fluid & Biomarkers 16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow
18 Chapter 17: Equipment Maintenance, Ethics & Regulatory Compliance
17.1 Equipment Maintenance, Calibration Schedules & Clinic Safety 17.2 Medical Ethics, Scope of Practice & Informed Consent 17.3 Patient Privacy, HIPAA Standards & Hazardous Waste Disposal
13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina
Key Takeaways Explain This Topic AI
The severe-NPDR 4-2-1 rule is met by hemorrhages or microaneurysms in four quadrants, venous beading in two or more quadrants, or prominent IRMA in at least one quadrant; two or more criteria indicate very severe NPDR.
PDR is defined by neovascularization or preretinal or vitreous hemorrhage, not by macular edema alone; diabetic macular edema can occur at any retinopathy stage.
Very high blood pressure with retinal hemorrhage, cotton-wool spots, exudates, or disc swelling may represent end-organ injury and requires immediate clinician and emergency evaluation.
Retinal findings may reflect autoimmune, infectious, hematologic, cardiovascular, neurologic, nutritional, thyroid, or malignant disease, so systemic history and medication review matter.
A technician documents findings and image quality; staging, prognosis, referral, and treatment remain licensed-clinician decisions.
Last updated: September 2026
Diabetic Retinopathy and Systemic Manifestations
The retina provides a view of neural tissue and microvasculature, so ocular findings can reflect both local disease and systemic health. Consistent documentation helps the clinician compare progression.
Diabetic retinopathy
Common nonproliferative findings include microaneurysms, dot-and-blot hemorrhages, hard exudates, cotton-wool spots, venous beading, and intraretinal microvascular abnormalities (IRMA). Proliferative disease is marked by neovascularization of the disc or elsewhere, or preretinal or vitreous hemorrhage associated with neovascular tissue.
The 4-2-1 rule supports recognition of severe NPDR:
- hemorrhages or microaneurysms meeting the reference severity in all four quadrants;
- definite venous beading in two or more quadrants;
prominent IRMA in at least one quadrant.
One criterion supports severe NPDR; two or more support very severe NPDR. A scenario that meets all three is not merely severe. Formal grading uses examination or validated photographic standards and clinician interpretation.
Diabetic macular edema can occur at any stage. OCT may show retinal thickening, intraretinal cysts, subretinal fluid, hyperreflective foci, or traction. Inspect segmentation and compare the same scan protocol. Do not infer activity from central thickness alone.
History includes diabetes type and duration, recent glycemic information if known, renal disease, pregnancy, blood pressure, lipid and smoking history, medications, and prior retinal treatment. The technician records values without prescribing systemic targets.
Hypertension and vascular disease
Hypertensive retinal findings can include arteriolar narrowing, arteriovenous crossing changes, hemorrhages, cotton-wool spots, hard exudates, and disc swelling. A very high pressure reading with acute retinal end-organ findings, neurologic symptoms, chest pain, dyspnea, or renal symptoms requires immediate clinician notification and emergency evaluation.
Repeat an unexpected blood pressure with correct cuff size and technique if protocol permits, but do not delay emergency response when the patient is unstable. Optic-disc swelling in this setting should be described objectively; the clinician determines whether the term papilledema or another diagnosis applies.
Other systemic categories
Autoimmune and inflammatory: lupus, sarcoidosis, vasculitis, and related disorders may produce vascular leakage, occlusion, uveitis, or choroidal findings.
Infectious: HIV-associated infections, tuberculosis, syphilis, herpes viruses, and other pathogens can affect retina or choroid. Appearance alone does not establish the organism.
Hematologic: sickle-cell disease, leukemia, anemia, hyperviscosity, and coagulopathy can alter perfusion or cause hemorrhage.
Neurologic and cardiovascular: embolic disease, carotid disease, stroke, and intracranial pathology can produce retinal or field findings.
Cancer: primary or metastatic tumors and treatment toxicity may involve choroid, retina, optic nerve, or orbit.
Medication toxicity: hydroxychloroquine, tamoxifen, and other agents have distinct screening patterns and risk factors.
Use respectful, precise terms. Historical nicknames may be memorable but can be stigmatizing or imprecise; describe the actual lesions.
Documentation workflow
Record laterality, location, extent, size reference, hemorrhage layer, exudation, vascular change, neovascularization, vitreous status, macular findings, pupil response, visual acuity, and imaging quality. Note comparison with prior photographs or OCT. If the finding is outside the technician's certainty, document what is seen rather than guessing.
- Finding Technical task Escalation focus
- New neovascularization or vitreous hemorrhage Comparable imaging and laterality Prompt clinician review
- New OCT fluid or traction Inspect segmentation and scan placement Route change, do not select treatment
Very high BP plus retinal end-organ findings Repeat correctly if safe; record symptoms Immediate clinician/emergency pathway
Possible infection or inflammation Record symptoms and images Urgent licensed evaluation
The exam tests recognition, but clinical practice requires objective reporting and supervised decisions.
Longitudinal documentation and systemic coordination
Record diabetes type and duration, recent glycated hemoglobin when available, blood pressure, renal disease, pregnancy status, medications, prior retinal treatment, and barriers to follow-up. These factors inform risk but do not let the technician grade disease from history alone. Imaging should be labeled by eye and field and should document artifacts or incomplete coverage. New vessels, hemorrhage, exudate, or edema are described objectively and routed for clinician interpretation.
The 4-2-1 rule applies to severe nonproliferative diabetic retinopathy: hemorrhages or microaneurysms in all four quadrants, venous beading in two or more quadrants, or prominent intraretinal microvascular abnormalities in at least one quadrant. Meeting any one criterion supports the severe category; meeting two or more is commonly termed very severe. Proliferative disease is defined by neovascularization or preretinal/vitreous hemorrhage, not simply by a high hemorrhage count. Sudden vision loss, new floaters, or a curtain needs urgent triage regardless of the last recorded grade.